From the Journals

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma


 

FROM BLOOD CELLS, MOLECULES AND DISEASES

Elotuzumab-based maintenance therapy may improve the posttransplant response for multiple myeloma (MM), according to the results of a small retrospective study at a single institution.

In addition, the therapies appear to be safely administered even to older patients because of the low rate of adverse effects, as indicated in a report published online in Blood Cells, Molecules and Diseases.

The researchers retrospectively evaluated the outcomes of seven MM patients who were started on elotuzumab-based maintenance (elotuzumab/lenalidomide/dexamethasone, elotuzumab/bortezomib/dexamethasone, or elotuzumab/bortezomib/methylprednisolone) following transplant, according to Xin Wang, MD, of the UMass Memorial Medical Center, Worcester, and colleagues.

The median age was 68 years (ranging from 56 years to 81 years) at the time of transplant, and median lines of induction therapy was 2; three patients (42.9%) had high-risk cytogenetics and five (71.4%) had stage II or greater disease at diagnosis.

Promising elotuzumab results

At a median follow-up of 24 months, five patients (71.4%) had improvement in their quality of response. Among all patients, there was a combined complete response (CR) or very good partial response (VGPR) rate increase from 57.1% to 100% (CR = 3, VGPR = 4). VGPR was defined by the researchers as an absence of abnormal immunofixation and soft tissue plasmacytoma without bone marrow biopsy.

All patients were alive without relapse or progression at the time of the final analysis. In terms of adverse effects, grade 3-4 events were observed in three (42.9%) of the patients. None of the patients discontinued the treatment because of intolerance, according to the researchers.

“Our study demonstrates that elotuzumab-based maintenance may deepen response post transplant in MM and can be safely administered even in older patients. Given its unique action and rare side effects, further studies of elotuzumab in the post-transplant setting are warranted,” the researchers concluded.

The study had no outside funding and the researchers reported that they had no disclosures.

SOURCE: Wang X et al. Blood Cells Mol Dis. 2020 Jul 28. doi: 10.1016/j.bcmd.2020.102482.

Recommended Reading

ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
MDedge Hematology and Oncology
Combo therapy with melflufen promising in small r/r multiple myeloma study
MDedge Hematology and Oncology
Transplant beats bortezomib-based therapy for MM, but questions remain
MDedge Hematology and Oncology
Vaccination regimen effective in preventing pneumonia in MM patients
MDedge Hematology and Oncology
Tandem transplantation, long-term maintenance may extend MM remission
MDedge Hematology and Oncology
Isa-Kd improves PFS in relapsed/refractory multiple myeloma
MDedge Hematology and Oncology
Transitioning regimen may prolong proteasome inhibitor–based therapy for MM
MDedge Hematology and Oncology
MM patients with concurrent AL show poor survival when coupled to cardiac dysfunction
MDedge Hematology and Oncology
E.U. gives thumbs up for belantamab in R/R multiple myeloma
MDedge Hematology and Oncology
FDA approves belantamab in relapsed/refractory multiple myeloma
MDedge Hematology and Oncology